Inhibitory effect of Kangjia Pill (抗甲丸) on thyrocyte proliferation in rat goiter model

Yong Han; Jing Zhou; Shu-jing Yu; Bin Cui; Hai-qing Zhang; Ling Gao; Jia-jun Zhao

doi:10.1007/s11655-009-0284-8

Your Location：

Home >

Browse articles >

Inhibitory effect of Kangjia Pill (抗甲丸) on thyrocyte proliferation in rat goiter model

Updated：2021-08-27

- Inhibitory effect of Kangjia Pill (抗甲丸) on thyrocyte proliferation in rat goiter model
- Chinese Journal of Integrative Medicine Vol. 15, Issue 4, Pages: 284-288(2009)
- Affiliations：
  
  1. Department of Endocrinology, Provincial Hospital Affiliated to Shandong University,Jinan,China
  2. Department of Endocrinology of Zaozhuang City Hospital,Shandong,China
  3. Scientific Centre, Shandong Provincial Hospital Affiliated to Shandong University,Jinan,China
- Author bio：
- Funds：
  
  Supported by the National Natural Science Foundation of China (No. 30672748), the Natural Science Foundation of Shandong Province (No. 22003C02), and the Shandong Administration of Traditional Chinese Medicine (No. 2005-070)
- DOI：10.1007/s11655-009-0284-8
  CLC：
- Published：2009，
  
  Published Online：18 August 2009，
Scan for full text
Han, Y., Zhou, J., Yu, Sj. et al. Inhibitory effect of Kangjia Pill (抗甲丸) on thyrocyte proliferation in rat goiter model., Chin. J. Integr. Med. 15, 284–288 (2009). https://doi.org/10.1007/s11655-009-0284-8

Yong Han, Jing Zhou, Shu-jing Yu, et al. Inhibitory effect of Kangjia Pill (抗甲丸) on thyrocyte proliferation in rat goiter model. [J]. Chinese Journal of Integrative Medicine 15(4):284-288(2009)
Han, Y., Zhou, J., Yu, Sj. et al. Inhibitory effect of Kangjia Pill (抗甲丸) on thyrocyte proliferation in rat goiter model., Chin. J. Integr. Med. 15, 284–288 (2009). https://doi.org/10.1007/s11655-009-0284-8 DOI：

Yong Han, Jing Zhou, Shu-jing Yu, et al. Inhibitory effect of Kangjia Pill (抗甲丸) on thyrocyte proliferation in rat goiter model. [J]. Chinese Journal of Integrative Medicine 15(4):284-288(2009) DOI： 10.1007/s11655-009-0284-8.

摘要

To investigate the inhibitory effects of Kangjia Pill (抗甲丸

KJP) on the cell proliferation in rat goiter model induced by methimazole (MMI). Fifty-six Wistar rats were randomly divided into four groups: the normal group

MMI model group (MMI)

low dose of KJP group (LKJP)

and high dose of KJP (HKJP). Except the normal group (20 rats)

the other groups (12 rats in each) were given 0.04% (w/v) MMI through the drinking water until the end of the experiment. One week later

the rats in the LKJP and HKJP groups were given KJP by gastrogavage at the dose of 250 mg/(kg · d) and 1 000 mg/(kg · d)

respectively for 12 weeks. The relative thyroid weight (mg/100 g body weight) of each rat was accessed. The expression of proliferating cell nuclear antigen (PCNA) was determined by immunohistochemistry

and the correlation analysis between the PCNA positive thyrocytes and the relative thyroid weight was performed. The expressions of PCNA and cyclin D1 were examined with Western blotting. After KJP treatment for 12 weeks

compared with the MMI group

the relative thyroid weight of the HKJP group decreased significantly

and the positive thyrocyte populations of PCNA in the two KJP groups reduced markedly (all P<0.05). The correlation analysis showed that PCNA was closely correlated with thyrocyte proliferation (r=0.685

P<0.05). KJP significantly decreased the protein expression of PCNA and cyclin D1 in the thyroid specimens (P<0.05)

the high dose showed better effects. KJP played a therapeutic role via inhibiting cell proliferation in the rat goitrous glands.

Abstract

To investigate the inhibitory effects of Kangjia Pill (抗甲丸

KJP) on the cell proliferation in rat goiter model induced by methimazole (MMI). Fifty-six Wistar rats were randomly divided into four groups: the normal group

MMI model group (MMI)

low dose of KJP group (LKJP)

and high dose of KJP (HKJP). Except the normal group (20 rats)

the other groups (12 rats in each) were given 0.04% (w/v) MMI through the drinking water until the end of the experiment. One week later

the rats in the LKJP and HKJP groups were given KJP by gastrogavage at the dose of 250 mg/(kg · d) and 1 000 mg/(kg · d)

compared with the MMI group

the relative thyroid weight of the HKJP group decreased significantly

P<0.05). KJP significantly decreased the protein expression of PCNA and cyclin D1 in the thyroid specimens (P<0.05)

the high dose showed better effects. KJP played a therapeutic role via inhibiting cell proliferation in the rat goitrous glands.

关键词

goiterChinese Medicinecell proliferationproliferating cell nuclear antigencyclin D1

Keywords

goiterChinese Medicinecell proliferationproliferating cell nuclear antigencyclin D1

references

Riesco JM, Juanes JA, Carretero J, Blanco EJ, Riesco-Lopez JM, Vazquez G, et al. Cell proliferation and apoptosis of thyroid follicular cells are involved in the involution of experimental non-tumoral hyperplastic goiter. Anat Embryol 1998;198: 439–450.

Tamura M, Kimura H, Koji T, Tominaga T, Ashizawa K, Kiriyama T, et al. Role of apoptosis of thyrocytes in a rat model of goiter. A possible involvement of Fas system. Endocrinology 1998; 139: 3646–3653.

Prelich G, Tan CK, Kostura M, Mathews MB, So AG, Downey KM, et al. Functional identity of proliferating cell nuclear antigen and a DNA polymerase-delta auxiliary protein. Nature 1987; 326: 517–520.

Dietrich DR. Toxicological and pathological applications of proliferating cell nuclear antigen (PCNA), a novel endogenous marker for cell proliferation. Crit Rev Toxicol 1993; 23: 77–109.

Connolly KM, Bogdanffy MS. Evaluation of proliferating cell nuclear antigen (PCNA) as an endogenous marker of cell proliferation in rat liver: a dual-stain comparison with 5-bromo-2′-deoxyuridine. J Histochem Cytochem 1993; 41: 1–6.

Jeong HS, Lee GK Song HG, Sung RH. Proliferative activity of thyroid lesions evaluated by mitotic count and proliferating cell nuclear antigen (PCNA). Korean J Pathol 1997;31: 1297–1307.

Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 1993; 7: 812–821.

DeGregori J, Kowalik T, Nevins JR. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes. Mol Cell Biol 1995; 15: 4215–4224.

Stacey DW. Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr Opin Cell Biol 2003;15: 158–163.

Patel VA, Hill DJ, Sheppard MC, Wang F, Logan A, Eggo MC. Apoptosis during goitre involution-the role of Bcl-2. J Endocrinol 2000;164: 323–330.

van Dierendonck JH, Wijsman JH, Keijzer R, van de Velde CJ, Cornelisse CJ. Cell-cycle-related staining patterns of anti-proliferating cell nuclear antigen monoclonal antibodies. Comparison with BrdUrd labeling and Ki-67 staining. Am J Pathol 1991;138: 1165–1172.

Maga G, Hubscher U. Proliferating cell nuclear antigen (PCNA): a dancer with many partners. J Cell Sci 2003; 116: 3051–3060.

Musaro A, McCullagh K, Paul A, Houghton L, Dobrowolny G, Molinaro M, et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 2001; 27: 195–200.

Shimomura Y, Matsuo H, Samoto T, Maruo T. Up-regulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma. J Clin Endocrinol Metab 1998;83: 2192–2198.

Sera N, Kawakami A, Nakashima T, Nakamura H, Imaizumi M, Koji T, et al. Fas/FasL mediated apoptosis of thyrocytes in Graves’ disease. Clin Exp Immunol 2001;124: 197–207.

Kusunoki T, Nakano T, Funasaka K, Murata K, Nishida S, Tomura T, et al. Proliferating cell nuclear antigen (PCNA) on human diseased thyroid cells. Nippon Jibiinkoka Gakkai Kaiho 1993;96: 651–658.

Shimizu T, Usuda N, Yamanda T, Sugenoya A, Iida F. Proliferative activity of human thyroid tumors evaluated by proliferating cell nuclear antigen/cyclin immunohistochemical studies. Cancer 1993;71: 2807–2812.

Laezza C, Mazziotti G, Fiorentino L, Gazzerro P, Portella G, Gerbasio D, et al. HMG-CoA reductase inhibitors inhibit rat propylthiouracil-induced goiter by modulating the ras-MAPK pathway. J Mol Med 2006; 84: 967–973.

Velicky J, Titlbach M, Lojda Z, Jelinek F, Vobecky M, Raska I. Expression of the proliferating cell nuclear antigen (PCNA) in the rat thyroid gland after exposure to bromide. Acta Histochem 1997; 99: 391–399.

Lee KE, Lee HJ, Kim YH, Yu HJ, Yang HK, Kim WH, et al. Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer. Jpn J Clin Oncol 2003; 33: 173–179.

Russo G, Claudio PP, Fu Y, Stiegler P, Yu Z, Macaluso M, et al. pRB2/p130 target genes in non-small lung cancer cells identified by microarray analysis. Oncogene 2003; 22: 6959–6969.

Benjamin DR, Gown AM. Aberrant cytoplasmic expression of proliferating cell nuclear antigen in Hodgkin’s disease. Am J Surg Pathol 1991;15:764–768.

Beier F, Lee RJ, Taylor AC, Pestell RG, LuValle P. Identification of the cyclin D1 gene as a target of activating 12. transcription factor 2 in chondrocytes. Proc Natl Acad Sci USA 1999; 96: 1433–1438.

Jiang L, Chen RS, Li JC. siRNA-cyclin D1 inhibit cell proliferation in breast cancer MCF-7 cell line. J Molecul Cell Biol (Chin) 2006; 39: 118–122.

Xiong W, Pestell RG, Watanabe G, Li J, Rosner MR, Hershenson MB. Cyclin D1 is required for S phase traversal in bovine tracheal myocytes. Am J Physiol 1997; 272: L1205–1210.

Yamamoto K, Hirai A, Ban T, Saito J, Tahara K, Terano T, et al. Thyrotropin induces G1 cyclin expression and accelerates G1 phase after insulin-like growth factor I stimulation in FRTL-5 cells. Endocrinology 1996; 137: 2036–2042.

Basolo F, Caligo MA, Pinchera A, Fedeli F, Baldanzi A, Miccoli P, et al. Cyclin D1 overexpression in thyroid carcinomas: relation with clinico-pathological parameters, retinoblastoma gene product, and Ki67 labeling index. Thyroid 2000;10: 741–746.

Lazzereschi D, Sambuco L, Carnovale Scalzo C, Ranieri A, Mincione G, Nardi F, et al. Cyclin D1 and Cyclin E expression in malignant thyroid cells and in human thyroid carcinomas. Int J Cancer 1998; 76: 806–811.

Nakashima M, Meirmanov S, Naruke Y, Kondo H, Saenko V, Rogounovitch T, et al. Cyclin D1 overexpression in thyroid tumours from a radio-contaminated area and its correlation with Pin1 and aberrant beta-catenin expression. J Pathol 2004; 202: 446–455.

Shi Y, Zou M, Varkondi E, Nagy A, Kozma L, Farid NR. Cyclin D1 in thyroid carcinomas. Thyroid 2001;11: 709–710.

Gadbois DM, Peterson S, Bradbury EM, Lehnert BE. CDK4/cyclin D1/PCNA complexes during staurosporine-induced G1 arrest and G0 arrest of human fibroblasts. Exp Cell Res 1995; 220: 220–225.

Sourisseau T, Georgiadis A, Tsapara A, Ali RR, Pestell R, Matter K, et al. Regulation of PCNA and cyclin D1 expression and epithelial morphogenesis by the ZO-1-regulated transcription factor ZONAB/DbpA. Mol Cell Biol 2006; 26: 2387–2398.

Zhang S, Zhu C, Liu Q, Wang W l. Effects of chloroquine on GFAP, PCNA and cyclin D1 in hippocampus and cerebral cortex of rats with seizures induced by pentylenetetrazole. J Huazhong Univ Sci Tech (Chin) Med Sci 2005;25: 625–628.

FULL TEXT LINK

More>

Views

420

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Experimental research on anti-tumor metastasis effect of basil polysaccharide in vivo

Future view and development of immunology: Exploring the immunology based on Chinese medicine and culture

Cost-effectiveness analysis of combined Chinese medicine and Western medicine for ischemic stroke patients

Objective tongue inspection on 142 liver cancer patients with damp-heat syndrome

Effect of Ermiao Recipe (二妙方) with medicinal guide Angelicae Pubescentis Radix on promoting the homing of bone marrow stem cells to treat cartilage damage in osteoarthritis rats

Related Author

No data

Related Institution

Institute of Basic Medicine, Qilu Hospital of Shandong University

Shandong University of Traditional Chinese Medicine

Institute of Gastroenterology, Shandong Provincial Hospital

Georg-August-Universität Göttingen, Göttingen

The Key Laboratory of Geriatrics, Beijing Hospital and Beijing Institute of Geriatrics’ Ministry of Public Health

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰